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Graphical abstract: Butyrate-producing bacteria are promising probiotic candidates to maintain 
gastrointestinal health. Here, the behavior and butyrogenic effect of such a candidate was assessed in a 
model for the gut microbiota.  
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2 
ABSTRACT 27 
Butyrate-producing bacteria are promising probiotic candidates to target microbial dysbiosis 28 
in gastrointestinal disorders like Inflammatory Bowel Diseases. Butyricicoccus 29 
pullicaecorum 25-3
T
, a butyrate-producing clostridial cluster IV strain, is such a candidate. 30 
Little is known about its abundance in the colon microbiota and its butyrogenic properties. 31 
We used the M-SHIME
®
, an in vitro simulator for the human intestinal microbial ecosystem, 32 
to study the effect of supplementing a single dose of B. pullicaecorum 25-3
T
 on lumen- and 33 
mucus-associated microbiota of eight individuals.  34 
B. pullicaecorum was more abundant in mucus-associated microbiota compared with lumen 35 
microbiota. Supplementation with a single dose of B. pullicaecorum 25-3
T
 resulted in a 36 
temporary increase in B. pullicaecorum bacteria in luminal compartment of all donors. In two 37 
cases, an increased butyrate production was observed as compared with the control. 16S 38 
rRNA gene amplicon sequencing revealed the microbiota of responders to be different as 39 
compared to non-responder microbiota. We can conclude that B. pullicaecorum 25-3
T
 is a 40 
mucus-associated bacterium whose potency to stimulate butyrate production is characterized 41 
by a large interindividual variability in terms of composition of the receiving microbial 42 
community. 43 
 44 
KEY WORDS 45 
Colonization, probiotic, gastrointestinal microbial ecology, in vitro, butyric acid, 46 
anaerobe 47 
  48 
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3 
1. INTRODUCTION 49 
The human gastrointestinal tract contains up to 100 trillion (10
14
) microbes which live 50 
in homeostatic symbiosis with their host and contribute to its health (Bäckhed, et al., 2005). 51 
Microbial dysbiosis is defined as a shift of the microbial composition and activity from a 52 
normal, beneficial state to one that could influence human health and contribute to disease 53 
(Frank, et al., 2011, Walker & Lawley, 2013). The onset and duration of several intestinal 54 
and systemic disorders have been linked to microbial dysbiosis (Alonso & Guarner, 2013, 55 
Walker & Lawley, 2013). This is also the case for Inflammatory Bowel Diseases (IBD), 56 
including Crohn’s Disease (CD) and Ulcerative Colitis (UC), which are characterized by a 57 
chronic, relapsing inflammation of the gastrointestinal tract. Microbial dysbiosis in IBD can 58 
be described by a loss in diversity of the dominant bacterial phyla (particularly Firmicutes), 59 
increased numbers of Proteobacteria and Actinobacteria and reduced numbers of anaerobic 60 
Firmicutes bacteria (Manichanh, et al., 2006, Frank, et al., 2007, Willing, et al., 2010, 61 
Lepage, et al., 2011). The reduction in Firmicutes bacteria is due to the loss of butyrate-62 
producing bacteria from clostridial cluster IV and XIVa. Butyrate is important to maintain 63 
gastrointestinal health, because it serves as the main energy source for gut epithelial cells, 64 
enhances epithelial barrier integrity and inhibits inflammation (Hamer, et al., 2008). 65 
Therefore, it has been suggested to target microbial dysbiosis by supplementing butyrate-66 
producing bacteria to restore homeostasis and health in IBD (Van Immerseel, et al., 2010).  67 
Butyricicoccus pullicaecorum 25-3
T
 is a butyrate-producing strain of the family 68 
Ruminococcaceae (clostridial cluster IV) with potential probiotic characteristics (Eeckhaut, et 69 
al., 2008). While the genus Butyricicoccus is decreased in abundance in stool samples of IBD 70 
patients, B. pullicaecorum 25-3
T
 is able to attenuate chemically induced colitis in a rodent 71 
IBD model (Eeckhaut, et al., 2012). In an in vitro study, we demonstrated a good intrinsic 72 
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4 
tolerance of B. pullicaecorum 25-3
T
 to stomach and small intestinal conditions which makes 73 
it suitable for probiotic application (Geirnaert, et al., 2014).  74 
To further assess the probiotic use of B. pullicaecorum 25-3
T
, it is important to know its 75 
behavior in the presence of a complex microbial community under colon conditions. In vitro 76 
models which simulate the human microbiota are a good tool to study the change in 77 
composition and metabolic activity after treatment with a probiotic, prebiotic, or other 78 
compound without the influence of the host (Venema & van den Abbeele, 2013). The M-79 
SHIME
®
 is such a model which simulates the mucosal and luminal human intestinal 80 
microbial ecosystem (Van den Abbeele, et al., 2012). The advantages of the M-SHIME
®
 over 81 
other common in vitro models are the incorporation of a mucus environment, conservation of 82 
butyrate-producing bacteria, and maintenance of interindividual differences in composition 83 
and activity of the microbiota in vitro (Van den Abbeele, et al., 2013). It has previously been 84 
used to study the colonization of microbiota of UC patients (Vermeiren, et al., 2012, 85 
Vigsnaes, et al., 2013) . 86 
Here, we use the M-SHIME
®
 to assess the colonization potential of B. pullicaecorum 87 
25-3
T
 and to analyze its impact on butyrate production by the microbiota of different 88 
individuals (healthy volunteers and CD patients in remission) after B. pullicaecorum 25-3
T
 89 
administration. We applied a single dose of B. pullicaecorum 25-3
T
 to monitor its growth or 90 
wash-out from the microbial communities during the 10 day follow-up period and effect of 91 
composition of receiving microbial community.  92 
 93 
2. MATERIALS AND METHODS 94 
2.1. Bacterial strain, growth conditions and preparation treatment 95 
Butyricicoccus pullicaecorum 25-3
T
 (LMG 24109
T
) was grown in anaerobic M2GSC 96 
medium at pH 6 prepared as described by Miyazaki et al. (Miyazaki, et al., 1997) but with 97 
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5 
15% (v/v) of clarified rumen fluid instead of 30% (v/v). M2GSC agar (1.5% w/v) plates were 98 
incubated at 37°C in an anaerobic (10% CO2, 90% N2) workstation (GP-Campus, Jacomex, 99 
TCPS NV, Rotselaar, Belgium) for 20h. Before use in each experiment, a B. pullicaecorum 100 
colony was transferred into 10 mL of anaerobic M2GSC broth and incubated overnight at 101 
37°C. Subsequently, the culture was subcultured (10% v/v) once in 500 mL anaerobic 102 
M2GSC broth and incubated for 20h at 37°C. The B. pullicaecorum culture was concentrated 103 
from 500 mL to 10 mL by centrifugation (10 min, 1500 g). The supernatant was removed and 104 
the pellet was resuspended in 10 mL anaerobic phosphate buffered saline (PBSS per L: 8.8g 105 
K2HPO4, 6.8g KH2PO4, 8 g NaCl, 1 g cysteine-HCl).  106 
2.2. Fecal bacteria from human volunteers 107 
Fecal bacteria of 3 healthy individuals (HV 1 – HV 3, aged 23-37) and 5 CD patients in 108 
remission (no  active inflammation) for more than 12 months (CD 1 – CD 5, aged 24-41) 109 
were prepared to inoculate M-SHIME. The study was approved by the Ethics Committee of 110 
the University Hospital Ghent (permit numbers EC UZG 2006/377 & EC UZG 2012/415), 111 
and all volunteers received and signed an informed consent form. None of the donors had 112 
received antibiotics or probiotics for at least 3 months before fecal sample donation. CD 1 – 113 
CD 3 received maintenance treatment with azathioprine (immunosuppressive drug) and CD 4 114 
and CD 5 had not taken any medication since 8 months before sample donation. CD 2, CD 4, 115 
and CD 5 had a history of ileitis, CD 1 and CD 3 had a history of ileocolitis. 116 
Fecal samples were collected in airtight containers together with one AnaeroGen sachet 117 
(Oxoid) to maintain anoxic conditions until start of incubation. Time between fecal sample 118 
donation and start of incubation was maximum 2h. A 20% (m/v) fecal suspension was 119 
prepared by homogenizing the fecal sample with 0.1 M anaerobic phosphate buffer (per L: 120 
8.8g K2HPO4, 6.8g KH2PO4 and 1g C2H3O2Sna, pH 6.8) in a stomacher for 2 min. After 121 
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6 
removing particulate material by centrifugation (2 min. at 500g) the suspension was used as 122 
inoculum for incubation.  123 
2.3. Simulation of luminal and mucosal microbiota – M-SHIME
®
 124 
The behavior of B. pullicaecorum was studied in the M-SHIME
®
, a dynamic in vitro 125 
model which simulates the mucosal and luminal human intestinal microbial ecosystem 126 
(ProDigest-Ghent University, Ghent, Belgium) (Van den Abbeele, et al., 2012, Van den 127 
Abbeele, et al., 2013). This model consists of pH controlled, stirred (200 rpm), airtight, 128 
double-jacketed glass vessels kept on 37°C and under anaerobic conditions by daily flushing 129 
with N2 (15 min). The setup used in this study consisted of a stomach and a small intestine 130 
vessel and two colon vessels (control and treatment) in parallel for each studied donor 131 
(Figure 1). The system was operated and simulation media were prepared as described earlier 132 
(Van den Abbeele, et al., 2013). The colon vessels were inoculated at the start with 40 mL 133 
fecal suspension in 500 mL nutritional medium. After an initial static incubation of 18 h, 134 
three times a day 140 mL nutritional medium and 60 mL pancreatic juice per colon vessel 135 
were supplemented to the small intestine vessel. Small intestine simulation suspension was 136 
divided over the colon vessels. The residence time in the colon vessels was 20 h and pH was 137 
controlled at pH 6.15- 6.40. To simulate mucosal microbiota, 60 mucin agar-covered 138 
microcosms in a polyethylene netting were added to each colon vessel. Mucin agar consisted 139 
of 5% (m/v) commercial pig gastric mucin and 1% (m/v) agar. Every two to three days 2/3 of 140 
the mucin agar-covered microcosms were replaced by fresh sterile ones under a flow of N2 to 141 
prevent disruption of anaerobic conditions. Seven days after inoculation, colon vessels were 142 
inoculated with 10 mL B. pullicaecorum culture (10
9
 bacteria/mL) (treatment vessels) or 10 143 
mL sterile anaerobic PBSS (control vessels). After treatment there was a follow-up period of 144 
10 days. Luminal samples were taken every day, mucin agar samples were taken every two to 145 
three days. Mucin agar-covered microcosms were washed with sterile PBSS to remove lumen 146 
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7 
bacteria. Mucin agar was removed from microcosms, homogenized and stored immediately at 147 
-20°C until further analysis.  148 
Previous studies showed a good reproducibility of the SHIME (Van den Abbeele, et al., 149 
2010). To validate the reproducibility during this study with an M-SHIME, we used the fecal 150 
slurry of 2 individuals (IBD 5 and HV 3) to inoculate each two identical M-SHIME colon 151 
vessels. SCFA concentrations in lumen samples of replicates were similar during the 152 
experiment of 17 days and confirmed reproducibility (Supplementary Figure 1). 153 
2.4. Short-Chain Fatty Acid (SCFA) analysis 154 
The SCFA in the luminal samples of the M-SHIME
®
 were extracted with diethyl ether 155 
and analyzed using a gas chromatograph as described by De Weirdt et al. (De Weirdt, et al., 156 
2010). The concentration in mM of acetate, propionate, butyrate, isobutyrate, valerate, 157 
isovalerate, caproate and isocaproate was determined in each sample. The concentration of 158 
acetate and butyrate was expressed as mol% which is the ratio of the concentration of acetate 159 
or butyrate (mM) and the total SCFA concentration (mM) multiplied by 100 in the sample. 160 
2.5. DNA extraction  161 
Liquid samples (1 mL fecal suspension and 1 mL lumen M-SHIME
®
) for total DNA 162 
extraction were centrifuged for 10 min at maximum speed, supernatant was removed and 163 
pellet was stored immediately at -20°C until further analysis.  164 
Total DNA was extracted from pellet of 1 mL liquid samples and 0.5 g mucin agar 165 
following a protocol adapted from Vilchez-Vargas et al. (Vilchez-Vargas, et al., 2013). Cells 166 
were lysed with 1 mL lysis buffer (100 mM Tris/HCl pH 8.0, 100 mM EDTA pH 8, 100 mM 167 
NaCl, 1% (m/v) polyvinylpyrrolidone and 2% (m/v) sodium docecyl sulphate) and 200 mg 168 
glass beads (0.11 mm, Sartorius) in a FastPrep
®
-96 instrument (MP Biomedicals, Santa Ana, 169 
USA) for two times 40 s (1600 rpm). After removing glass beads by centrifugation (5 min at 170 
maximum speed), DNA was extracted from supernatant following a phenol-chloroform 171 
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8 
extraction. DNA was precipitated with 1 volume ice-cold isopropyl alcohol and 0.1 volume 3 172 
M sodium acetate for at least 1 h at -20°C. After removal of isopropyl alcohol by 173 
centrifugation (30 min, maximum speed) the DNA pellet was dried and resuspended in 100 174 
µL (fecal sample) or 30 µL (M-SHIME
®
 sample) 1x TE (10 mM Tris, 1 mM EDTA) buffer. 175 
After finishing the extraction protocol, DNA samples were immediately stored at -20°C until 176 
further analysis.  177 
Quality of DNA samples was analyzed by 1% (w/v) agarose (Life technologies
TM
, 178 
Madrid, Spain) gel electrophoresis. DNA was quantified by a fluorescence assay with the 179 
QuantiFluor
®
 dsDNA kit (Promega, Madison, USA) and Glomax
®
-Multi+ system (Promega, 180 
Madison, USA). 181 
2.6. qPCR 182 
Total bacterial 16S rRNA gene and species specific 16S rRNA gene of B. 183 
pullicaecorum was quantified with qPCR in 100-fold diluted DNA extracts of fecal and M-184 
SHIME
®
 samples. All qPCR assays were performed on a StepOnePlus
TM
 Real-Time PCR 185 
system (Applied Biosystems, Carlsbad, CA). The amplification reactions were carried out in 186 
triplicate in a volume of 25 µL which contained 20 µL of in-house prepared mastermix and 5 187 
µL of DNA template. The in-house prepared mastermix was comprised of 1x Colorless 188 
GoTaq
®
 reaction buffer (Promega), 1.5 mM MgCl2 , 200 nM dNTP mix, 200 nM of each 189 
forward and reverse primer, 0.625 U GoTaq
®
 HotStart polymerase (Promega) and 0.1x 190 
SYBR
®
 Green I (Invitrogen
TM
, provided at 10 000x, stock solutions of 20x were prepared in 191 
DMSO). Primers for total Bacteria (PRBA 338f and 518r) amplified a 180 bp amplicon of V3 192 
region of the 16S rRNA gene (Ovreas, et al., 1997). Cycling program for total bacteria was as 193 
follows: 3 min at 95°C followed by 40 cycles of 1 min at 95°C, 40 s at 56°C and 40 s at 72°C. 194 
Species specific primers were designed and synthesized by PrimerDesign Ltd. (Southampton, 195 
UK) and amplified a 126 bp amplicon of the 16S rRNA gene of B. pullicaecorum. Primer 196 
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9 
sequences of forward primer was 5’- GAGGCAGCAGTGGGGAA and reverse primer 5’- 197 
TCTTCAGGTACCGTCATTTGTT. Program was as follows: 3 min at 95°C followed by 40 198 
cycles of 1 min at 95°C, 40 s at 54.5°C and 40 s at 72°C.  199 
2.7. Illumina 200 
The V3-V4 region of the 16S rRNA gene was amplified with primer pair 341F and 201 
785R, with dual multiplex identifier (MID) and adaptors as described by Kozich et al (2013, 202 
AEM). Sequencing was performed using Illumina MiSeq sequencer and sequencing kit 203 
MiSeq V3 to produce 300 bp pair-end reads. After de-multiplexing, fastq sequences were 204 
merged using FLASH (Magoc & Salzberg, 2011) software with default parameters, and 205 
successfully combined reads were filtered based on quality (>90% of nucleotides must have 206 
quality score 30 or higher for every read) using Fastx tool kit 207 
(http://hannonlab.cshl.edu/fastx_toolkit/). A minimum of 3,000 reads was obtained for each 208 
sample included in the study. Chimeras were removed using UCHIME (Egdar et al 2013) and 209 
each sample was standardized to 3,000 reads using random selection of reads. The taxonomy 210 
of reads was determined using RDP classifier (Wang et al 2007) and taxonomy tables were 211 
created using Perl scripts.  212 
2.8. Statistical analysis 213 
All statistical analyses were performed in R. Bray-Curtis dissimilarity was the major 214 
beta-diversity measure used in this study and was calculated using package “vegan” (Dixon 215 
2003); alpha diversity measures included Chao1 richness measurement, observed number of 216 
genera/OTUs and Shannon evenness, all calculated in “vegan” as well. “adonis” (analysis of 217 
dissimilarity, multidimensional ANOVA of distance matrices) was used to determine the 218 
variation explained by different factors tested in the study, as well as the significances. 219 
Constrained analysis of principal coordinates (‘capscale’, Anderson & Willis, 2003) was used 220 
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10 
to perform coordination of samples according to the variable being tested and determine the 221 
relative importance of difference variables. 222 
 223 
3. RESULTS 224 
3.1. Relative B. pullicaecorum abundance increased in the mucosal microbial 225 
community compared with luminal microbial community of the M-SHIME
®
 226 
Colon vessels of the M-SHIME
®
 were inoculated with fecal suspensions of one 227 
individual and in total eight incubations were performed with fecal suspensions of eight 228 
different individuals (CD1-5; HV1-3). During a period of seven days, fecal bacteria were able 229 
to colonize the lumen and/or mucus environment of the in vitro model. The concentration of 230 
bacteria (total 16S rRNA gene) and indigenous B. pullicaecorum (species-specific 16S rRNA 231 
gene assay) was determined by qPCR to determine the initial levels of B. pullicaecorum 232 
before supplementation. Luminal concentrations of total bacteria on day 7 ranged from 7.6 to 233 
9.0 log copies/mL with a median at 8.5 log copies/mL while mucosal concentrations ranged 234 
from 8.9 to 9.9 log copies/g with a median of 9.4 log copies/g. Luminal concentrations of B. 235 
pullicaecorum varied from 4.3 to 6.2 log copies/mL with a median at 5.5 log copies/mL 236 
while mucosal concentrations ranged from 6.3 to 7.8 log copies/mL with a median at 7.2 log 237 
copies/mL. Overall, there was no difference in concentration of total and B. pullicaecorum 238 
bacteria between CD and HV microbiota in the M-SHIME (data not shown). The ratio of B. 239 
pullicaecorum 16S rRNA gene copies to total 16S rRNA gene copies was used to calculate 240 
the relative abundance of B. pullicaecorum in the luminal versus mucosal microbiome. B. 241 
pullicaecorum was relatively more abundant (p<0.0001) in mucosal microbial community 242 
(0.85 ± 0.14 %) than the luminal microbial community (0.16 ± 0.03 %) (Figure 2A). 243 
3.2. Treatment of microbial communities with single dose B. pullicaecorum 25-3
T
 244 
On day seven, the treatment vessels were supplemented with a single dose of B. 245 
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11 
pullicaecorum 25-3
T
 (on average 9 log copies/mL M-SHIME
®
 suspension). Before 246 
supplementation, there was no difference in average concentrations of total bacteria and B. 247 
pullicaecorum in lumen and mucus samples of treated vessels compared with control vessels 248 
(Supplementary Figure 2 and Figure 2. B1). Three days after treatment the mean 249 
concentration of B. pullicaecorum was higher (p = 0.005) in lumen of treated vessels 250 
compared with control vessels (Figure 2.B2). This was not the case in mucus samples. If we 251 
compare treatment with control concentrations in each individual microbial community there 252 
were more B. pullicaecorum in mucus samples of treated vessels compared with control in 4 253 
out of 8 cases (Supplementary Figure 3). Ten days after supplementation B. pullicaecorum 254 
concentration in the treated vessels was similar to those in the control vessels (Figure 2.B3). 255 
Based on 16S rRNA gene amplicon sequencing, we observed a clear increase in relative 256 
abundances of Butyricicoccus spp. in treated lumen and mucus samples of CD 1, CD 4, CD 5, 257 
HV 1, HV 2 and HV 3 three days after treatment (Supplementary Table S1). Seven days after 258 
treatment, Butyricicoccus was still higher in mucus samples of treated vessels compared to 259 
control of CD 4, CD 5, HV 1, HV 2 and HV 3.  260 
3.3. SCFA profiles show inter-individual differences after treatment with B. 261 
pullicaecorum 25-3
T
  262 
Short-Chain Fatty Acid (SCFA) concentrations were determined in lumen samples to 263 
evaluate the metabolic activity of the different microbial communities in the M-SHIME
®
. 264 
The mean concentrations of total SCFA during the startup period (day 3- day 7) ranged from 265 
38.6 (± 2.8) to 58.5 (± 4.2) mM in the 16 M-SHIME
®
 vessels (Table 1). There were inter-266 
individual differences in the SCFA profile. The relative concentration of 267 
acetate/propionate/butyrate for example ranged from 50%/20%/20% (CD 3, control) to 268 
73%/13%/11% (HV1, control). Higher inter-individual differences were observed in case of 269 
branched chain fatty acids (BCFA) levels ( 1% to 10%). There was no difference in SCFA 270 
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12 
profiles between control and treatment vessels of each corresponding donor microbial 271 
community. SCFA profiles of CD microbiota were comparable to those of HV microbiota in 272 
the M-SHIME. On average, single dose of B. pullicaecorum 25-3
T
 did not increase SCFA 273 
production during a ten days follow-up period (Table 1). In two cases (CD 5 and HV 1), a 274 
clear difference in SCFA profile was observed between treatment and control (Figure 3). In 275 
case of donor CD 5, the relative concentration of acetate started to decrease after 4 days of 276 
supplementation to 53% (day 14, control level 74%), whereas, the relative concentration of 277 
butyrate increased to a level of 18% (day 14, control level 8%). In case of donor HV 1, the 278 
relative concentration of acetate decreased to 53% (day 13, control level 71%) and the 279 
relative concentration of butyrate increased to 22% (day 13, control level 7%).  280 
3.4. Responder microbiota different from non-responder microbiota 281 
 To investigate the basis of differences in butyrate/acetate production, we defined 282 
groups of “responders” (RS, samples that responded to the inoculation and showed increase 283 
in butyrate production compared to controls without inoculations, i.e. CD5 and HV1) and 284 
“non-responders” (NR, the rest). We did not find significant differences in alpha-diversity 285 
between NR and RS samples (Wilcox test p>0.05 in lumen and mucus). However, significant 286 
differences were observed between RS and NR samples from the control lumen (21.9% 287 
variation in genus, p=0.002) and mucus (23.6% variation of genus, p=0.002, Figure 4) were 288 
found, indicating a distinct profile for non-treated RS microbiome. We analysed the major 289 
genera (those with average abundance >0.5% in the control samples, n=24) using Wilcox test 290 
and discovered four genera with significant differences (p<0.05) between the NR and RS 291 
control samples in the lumen and seven in the mucus (Figure 5).  292 
In the NR group no significant differences were found between samples after treatment 293 
and control (all p >0.05), nor in the mucus samples of the RS samples; nevertheless, 294 
significant differences were found between the lumen samples of the treatment and control in 295 
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13 
the RS group (33.5% variation in genus variation, p=0.035). We examined the major genera 296 
(defined using similar criteria as above, n=21) using Wilcox test between the RS control 297 
samples and treatment samples, where we found three genera exhibiting significant 298 
differences between control and treatment (Figure 6). A significant increase of Anaeroglobus 299 
and Sutterella was found in the RS after treatment, while Citrobacter decreased, and no 300 
significant changes were found in the NR (Figure 6).  301 
 302 
4. DISCUSSION 303 
The objective of this study was to assess the in vitro colonization preference of 304 
indigenous B. pullicaecorum from eight individuals and evaluate the colonization ability of a 305 
B. pullicaecorum isolate 25-3
T
 in the luminal and mucosal microbiome after a single 306 
supplementation. We further assessed whether a single dose of B. pullicaecorum 25-3
T
 307 
resulted in increased butyrate production by the in vitro simulated gut microbiome. Finally, 308 
the effect of the inoculation of B. pullicaecorum 25-3
T
 on the microbiota composition was 309 
analyzed.  310 
B. pullicaecorum was more abundant in mucin- associated microbiota of the M-SHIME 311 
which is a first indication that it will also associate with the mucus layer in the gut. This 312 
confirms previous studies where the genus Butyricicoccus was detected in human mucosal 313 
biopsy samples, Nava et al. reported Butyricicoccus at mean relative abundances of 1-2% 314 
(Frank, et al., 2011, Nava & Stappenbeck, 2011, Durbán, et al., 2012, Harrell, et al., 2012, 315 
Ng, et al., 2013). This corresponds with the mean relative abundance of B. pullicaecorum in 316 
the mucin-associated microbiota of 0.85% in our study. Association with the intestinal 317 
mucosa is a key characteristic in selection of novel probiotic bacteria because it is important 318 
for immune modulation, resistance to pathogen colonization, enhanced mucosal healing and 319 
prolonged residence time in the gut (Ouwehand, et al., 2002). The relative abundance of B. 320 
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14 
pullicaecorum in lumen M-SHIME samples (0.02 % - 0.34 %) was comparable with 321 
previously reported relative abundances of Butyricicoccus spp. in human fecal samples 322 
(0.05% - 0.4%) (Claesson, et al., 2012, Schnorr, et al., 2014). We conclude that 323 
Butyricicoccus has affinity for colonizing the mucosal environment.  324 
Supplementation with a single dose of B. pullicaecorum 25-3
T
 resulted in a temporary 325 
increase in B. pullicaecorum bacteria in lumen microbiota of all individuals. The difference 326 
in B. pullicaecorum concentration between treated and non-treated colon compartments was 327 
gone ten days after treatment. This indicates that B. pullicaecorum 25-3
T
 is only able to 328 
temporarily colonize the microbiota after a single supplementation. The persistence of 329 
traditional probiotics, Lactobacillus and Bifidobacterium species, is also generally low 330 
(Lawley & Walker, 2013). For example, in a trial with Lactobacillus reuteri, the 331 
supplemented strain was no longer detected in the majority of participants four days after 332 
stopping the treatment (Rattanaprasert, et al., 2014). To successfully colonize the gut 333 
microbiota, the supplemented species has to compete with the established resident microbiota 334 
for niches and nutrients (Lawley & Walker, 2013). The mucosal niche is thought to be 335 
saturable and will already contain a specific population (Gibson, et al., 2014), which makes it 336 
less obvious for exogenous strains to colonize that niche. The colonization resistance of the 337 
resident microbiota towards exogenous strains can be obtained through physical exclusion 338 
and/or production of antimicrobials, but will also depend on interindividual differences in 339 
composition of the endogenous microbiome.. For example, in a double blinded, placebo-340 
controlled crossover study with vaginal administration of two probiotic Lactobacillus strains, 341 
the supplemented strains were only detected in 7 of 12 cases after probiotic treatment (Bisanz, 342 
et al., 2014).  Such studies correspond with our finding of a variable success in B. 343 
pullicaecorum 25-3
T
 colonization in the eight human-derived microbiota.  344 
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15 
We identified two responder microbiota that displayed a clear increase in butyrate 345 
levels upon the single supplementation of B. pullicaecorum 25-3
T
, compared to non-treated 346 
microbiota. It is noteworthy that responder microbiota already displayed lower butyrate 347 
levels than non-responder microbiota prior to the treatment. Interestingly, the increase in 348 
butyrate levels for the responder microbiota was concomitant with a decrease in acetate levels. 349 
This indicates the presence of cross-feeding which is the metabolic interaction between 350 
acetate-consuming and butyrate-producing microbiota (De Vuyst & Leroy, 2011). It is known 351 
that many butyrate-producing bacteria, including B. pullicaecorum, follow the butyryl-CoA: 352 
acetate CoA-transferase pathway (Vital, et al., 2014), which converts intra- and extra-cellular 353 
acetate and intracellular butyryl-CoA into butyrate and acetyl-CoA (Louis & Flint, 2009).  354 
Only two out of eight microbiota were responsive to B. pullicaecorum supplementation 355 
in terms of butyrate production. Studies with murine models reported a general increase in 356 
butyrate production after treatment with butyrate-producing Clostridium tyrobutyricum, 357 
Butyrivibrio fibrisolvens or Eubacterium limosum (Okamoto, et al., 2000, Asanuma, et al., 358 
2001, Ohkawara, et al., 2005, Kanauchi, et al., 2006, Possemiers, et al., 2008, Hudcovic, et 359 
al., 2012). However, the variability in response was not characterized as biological specimens 360 
from different animals were pooled. It is not clear in our study whether higher butyrate levels 361 
in the responder microbiota result from a direct effect – butyrate production by supplemented 362 
B. pullicaecorum 25-3
T
 – or an indirect effect – stimulation of the butyrate-producing 363 
community by supplemented B. pullicaecorum 25-3
T
. While the SHIME model has been 364 
successful in demonstrating increased butyrate production upon supplementation of the 365 
butyrate-producing E. limosum (Possemiers, et al., 2008), the impact on the endogenous 366 
microbiome needs further characterization. 367 
The original (non-treated) composition of luminal and mucosal microbiota from 368 
responders and non-responders revealed significant differences. A couple of genera were 369 
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16 
significantly increased or decreased but no clear specific phylogenetic background was 370 
identified. With respect to the change in RS microbiota upon B. pullicaecorum treatment, 371 
Anaeroglobus and Sutterella were the two genera that significantly increased compared to the 372 
control. Anaeroglobus is a relatively new taxon and is reported to have the ability to produce 373 
butyrate; the butyrate producing ability of the Sutterella genus is less clear (Carlier, et al., 374 
2002). The genus Sutterella was recently described as one of the genera detected less 375 
frequently among pouchitis and Crohn’s disease-like patients compared to non-inflamed 376 
control (Tyler, et al., 2013). Phylogenetically different species in the human gut can perform 377 
similar (metabolic) functions and this leads to a functional core microbiome instead of a 378 
phylogenetic core microbiome (Lozupone, et al., 2012). This functional redundancy makes it 379 
difficult to link the observed differences in composition of the responder microbiota to its 380 
function. Therefore, it is not yet clear what explains the effect of the treatment with B. 381 
pullicaecorum 25-3
T
 on butyrate production in the two responder microbiota.  382 
We can conclude that B. pullicaecorum is an efficient colonizer of the mucus 383 
environment. While a single treatment with B. pullicaecorum 25-3
T
 did not result in a 384 
persistent colonization, it was effective in increasing mucosal B. pullicaecorum levels in four 385 
out of eight cases up to 10 days after treatment, and in stimulating butyrate production in two 386 
out of eight cases. While the original (non-treated) responder microbiota significantly 387 
differed from non-responder microbiota and shifts in the responder microbiome were noted 388 
upon B. pullicaecorum 25-3T administration, the factors for explaining the variability in 389 
response need to be investigated in studies with more individuals. 390 
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Table 1: Total SCFA concentration (mM) during start-up (day 3 – day 7) and follow-up (day 8 – day 17) period and levels of acetic 
acid (AA), propionic acid (PA), butyric acid (BA) and branched chain fatty acids (BCFA) during start-up period. Data are means with 
SE.  
  Total SCFA (mM) AA/PA/BA (%) BCFA (%) 
  Start-up Follow-up Start-up Follow-up Start-up Follow-up 
CD 1 C 38.6  (2.8) 39.1 (1.4) 57/15/20 (4/0/2) 45/15/29 (1/0/0) 7 (2) 11 (0) 
 T 42.5  (3.3) 42.6 (2.3) 62/15/17 (3/0/2) 48/15/26 (1/0/0) 5 (2) 11 (0) 
CD 2 C 58.5  (4.2) 51.8 (2.5) 47/22/19 (2/1/0) 58/20/18 (2/1/0) 9 (1) 4 (1) 
 T 56.3  (3.4) 53.1 (2.3) 46/23/20 (1/1/0) 55/21/18 (1/0/0) 10 (0) 7 (1) 
CD 3 C 42.3  (2.0) 43.7 (1.1) 65/17/16 (2/0/1) 67/17/13 (1/0/0) 2 (1) 3 (1) 
 T 38.9  (2.1) 39.6 (2.1) 62/18/16 (2/0/1) 64/18/15 (1/0/0) 3 (1) 3 (1) 
CD 4 C 49.1  (5.2) 48.1 (2.3) 50/20/20 (3/2/1) 50/16/25 (2/0/1) 5 (1) 9 (1) 
 T 56.7  (1.8) 51.0 (2.7) 52/17/22 (2/1/1) 53/16/24 (2/0/1) 4 (1) 7 (1) 
CD 5 C 45.3  (2.1) 41.5 (1.4) 68/14/13 (0/1/0) 73/17/8 (1/0/0) 4 (0) 2 (0) 
 T 43.7  (1.5) 43.7 (2.0) 70/15/12 (1/0/0) 62/16/15 (2/0/1) 2 (0) 6 (1) 
HV 1 C 45.3  (3.2) 41.9 (1.8) 73/13/11 (2/0/1) 72/15/8 (1/0/0) 1 (0) 6 (1) 
 T 44.8  (2.7) 44.1 (2.1) 71/14/12 (0/0/0) 57/16/19 (2/0/1) 2 (0) 8 (0) 
HV 2 C 43.1  (1.9) 39.7 (1.3) 68/13/16 (1/0/1) 58/17/18 (2/0/1) 1 (0) 7 (1) 
 T 44.4  (3.1) 42.7 (2.2) 70/14/15 (0/0/0) 58/17/18 (2/0/1) 1 (0) 7 (1) 
HV 3 C 46.7  (2.9) 40.6 (1.9) 68/14/13 (1/0/1) 60/17/16 (1/0/1) 4 (0) 8 (1) 
 T 42.0  (1.5) 43.1 (1.5) 66/15/17 (1/1/0) 59/14/17 (2/0/1) 1 (0) 8 (0) 
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FIGURE LEGENDS 1 
Figure 1 2 
Overview of experimental set-up of simulation mucosal and luminal microbiota in M-3 
SHIME
®
. In total 8 simulations of 17 days were performed starting with fecal microbiota of 8 4 
different individuals. Treatment vessels were supplemented on day 7 with one dose of B. 5 
pullicaecorum (10
9
/mL).  6 
 7 
Figure 2 8 
qPCR analysis of mucosal and luminal communities in M-SHIME
®
. 9 
A) Boxplot of relative abundance of B. pullicaecorum (16S rRNA gene copy number B. 10 
pullicaecorum/ Total 16S rRNA gene) in lumen samples (n = 16) and mucus samples (n = 16) 11 
after 7 days in M-SHIME
®
 and before treatment. Black lines within boxplot represent median 12 
values and whiskers indicate minimum and maximum value. Means +/- standard error are shown 13 
above each boxplot. B) Concentration of B. pullicaecorum (log copies/mL or /g) in lumen and 14 
mucus samples of control (C) and treatment (T) vessels before treatment (B1), three days after 15 
treatment (B2) and ten days after treatment (B3). Each data point represents an individual M- 16 
SHIME
® 
sample. Limit of detection (LOD) is indicated by grey horizontal line. Significant 17 
differences are indicated by asterisks with ** = p<0.001; *** = p<0.0001  and ns = non-18 
significant.  19 
 20 
Figure 3 21 
Relative concentration of acetate () and butyrate (●) in mol% (Ration mM acetate or 22 
butyrate and mM total SCFA) in lumen samples of control (---; open) and treated (—; full) 23 
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vessels of M-SHIME
®
. Dashed vertical line on day 7 indicates single treatment with B. 24 
pullicaecorum (10
9
/mL). 25 
 26 
Figure 4 27 
Constrained analysis of principle coordinates based on Bray-Curtis distance from genera 28 
composition, constrained by sample type (Lumen vs Mucus) and response (NR vs RS). CAP1 29 
and CAP2 represent the major axes of separations calculated from ‘capscale’, and NR/RS 30 
composes the most primary separation of communities (CAP1) while lumen/mucus samples 31 
composes secondary separations (CAP2). 32 
 33 
Figure 5 34 
Boxplots of genera that are significantly different between NR and RS control lumen and 35 
mucus samples. P-values are from Wilcox test without multiple testing corrections.   36 
 37 
Figure 6 38 
Boxplots of genera that are significantly different between treatment and control lumen 39 
samples in RS, NR samples were also added to show the differences in response to treatment. P-40 
values are from Wilcox test without multiple testing corrections.   41 
 42 
Supplementary Figure 1 43 
Reproducibility of M-SHIME. Fecal sample of  two individuals was used to inoculate each 44 
two identical M-SHIME colon vessels. SCFA concentrations of lumen fractions for vessel 1 (○, 45 
....
) and vessel 2 (●, ---) for IBD 5 (A) and HV 3 (B). 46 
 47 
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Supplementary Figure 2 48 
qPCR analysis of mucosal and luminal communities in M-SHIME
®
. 49 
Concentration of Bacteria (log copies/mL or /g) in lumen and mucus samples of control (C) 50 
and treatment (T) vessels before treatment, three days after treatment and ten days after 51 
treatment. Each data point represents an individual M- SHIME
® 
sample. Limit of detection 52 
(LOD) is indicated by grey horizontal line. Significant differences are indicated by asterisks with 53 
** = p<0.001; *** = p<0.0001  and ns = non-significant.  54 
 55 
Supplementary Figure 3 56 
Log difference of B. pullicaecorum concentration in treatment and control in lumen and 57 
mucus samples after 3 and 10 days of single treatment of different donor microbiota. 58 
 59 
Supplementary Figures 4 60 
Constrained analysis of principle coordinates of Bray-Curtis distance based on sample type. 61 
The major separation is between faecal and other samples (CAP1) while the separation between 62 
lumen and mucus is less prominent (CAP2).  63 
 64 
Supplementary Figure 5 65 
Constrained analysis of principle coordinates based on Bray-Curtis distance from genera 66 
composition, constrained by sample type (Lumen vs Mucus) and health status (HV vs CD). 67 
CAP1 and CAP2 represent the major axes of separations calculated from ‘capscale’, and 68 
lumen/mucus composes the most primary separation of communities (CAP1) while CD/HV 69 
samples composes secondary separations (CAP2). 70 
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Figure 1  
Overview of experimental set-up of simulation mucosal and luminal microbiota in M-SHIME®. In total 8 
simulations of 17 days were performed starting with fecal microbiota of 8 different individuals. Treatment 
vessels were supplemented on day 7 with one dose of B. pullicaecorum (109/mL).  
149x149mm (150 x 150 DPI)  
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Figure 2  
qPCR analysis of mucosal and luminal communities in M-SHIME®.  
A) Boxplot of relative abundance of B. pullicaecorum (16S rRNA gene copy number B. pullicaecorum/ Total 
16S rRNA gene) in lumen samples (n = 16) and mucus samples (n = 16) after 7 days in M-SHIME® and 
before treatment. Black lines within boxplot represent median values and whiskers indicate minimum and 
maximum value. Means +/- standard error are shown above each boxplot. B) Concentration of B. 
pullicaecorum (log copies/mL or /g) in lumen and mucus samples of control (C) and treatment (T) vessels 
before treatment (B1), three days after treatment (B2) and ten days after treatment (B3). Each data point 
represents an individual M- SHIME® sample. Limit of detection (LOD) is indicated by grey horizontal line. 
Significant differences are indicated by asterisks with ** = p<0.001; *** = p<0.0001  and ns = non-
significant.  
202x164mm (300 x 300 DPI)  
 
 
Page 29 of 39
ScholarOne Support 1-434/964-4100
FEMS Microbiology Ecology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 3  
Relative concentration of acetate (→) and butyrate (●) in mol% (Ration mM acetate or butyrate and mM 
total SCFA) in lumen samples of control (---; open) and treated (—; full) vessels of M-SHIME®. Dashed 
vertical line on day 7 indicates single treatment with B. pullicaecorum (109/mL).  
168x195mm (150 x 150 DPI)  
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1 
SUPPLEMENTARY INFO  1 
A minimum of 3,000 reads was obtained for each sample included in the study, and the 2 
composition resembles that of typical human fecal/gut microbiome. At phylum level, 3 
Firmicutes (44.7+-16.4%), Proteobacteria (23.3+-11.8%) and Bacteroidetes (22.4+-17.7%) 4 
are the major phyla; while at genus level, the unclassified_Lachnospiraceae (18.4+-9.8%), 5 
unclassified_Enterobacteriaceae (10.9+-10.2%), and Bacteroides (15.2+-13.1%) are 6 
respectively the major  genera of the dominant phyla.  7 
We examined the relative contribution of different variables that could contribute to the 8 
variations of the microbiome (Bray-Curtis dissimilarities based on genera composition) using 9 
“adonis”. Donor individuals have the largest effect on the microbiome and explain 32.7% of 10 
community variations based on genus composition (p=0.001). Type of samples (fecal, mucus 11 
and lumen) has second largest effect (15.2% variation, p=0.001), and thus different samples 12 
were analyzed separately, with a focus on lumen and mucus samples. (Supplementary figure 13 
4). The disease status (healthy versus CD) has smaller yet significant effect in mucus (12.5% 14 
variation, p=0.003) and lumen (11.8% variation, p=0.002), but not significant in fecal 15 
samples possibly due to the small sample size (n=8) (Supplementary figure 5). Control versus 16 
treatment and time since treatment do not have significant effect on the microbial 17 
composition alone or combined (all p>0.05), and no significance is found when they are 18 
limited to lumen or mucus samples (all p>0.05).  19 
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Supplementary Table 1: Relative abundance of genus Butyricicoccus (16S rRNA gene amplicon sequencing) 
  Butyricicoccus spp. 
  3 days after treatment 7 days after treatment 
  Mucus Lumen Mucus Lumen 
CD 1 C 5 3 3 12 
 T 30 27 3 3 
CD 2 C 0 1 1 2 
 T 2 2 1 0 
CD 3 C 6 6 4 9 
 T 3 9 3 9 
CD 4 C 2 5 11 0 
 T 21 28 6 1 
CD 5 C 0 2 3 1 
 T 106 360 14 1 
HV 1 C 4 6 2 1 
 T 113 321 15 2 
HV 2 C 7 15 7 5 
 T 207 458 17 4 
HV 3 C 6 3 5 1 
 T 124 385 12 1 
 
Page 35 of 39
ScholarOne Support 1-434/964-4100
FEMS Microbiology Ecology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Supplementary Figure 1  
Reproducibility of M-SHIME. Fecal sample of  two individuals was used to inoculate each two identical M-
SHIME colon vessels. SCFA concentrations of lumen fractions for vessel 1 (○, ....) and vessel 2 (●, ---) for 
IBD 5 (A) and HV 3 (B).  
176x119mm (150 x 150 DPI)  
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Supplementary Figure 2  
qPCR analysis of mucosal and luminal communities in M-SHIME®.  
Concentration of Bacteria (log copies/mL or /g) in lumen and mucus samples of control (C) and treatment 
(T) vessels before treatment, three days after treatment and ten days after treatment. Each data point 
represents an individual M- SHIME® sample. Limit of detection (LOD) is indicated by grey horizontal line. 
Significant differences are indicated by asterisks with ** = p<0.001; *** = p<0.0001  and ns = non-
significant.  
 
69x190mm (150 x 150 DPI)  
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Supplementary Figure 3  
Log difference of B. pullicaecorum concentration in treatment and control in lumen and mucus samples after 
3 and 10 days of single treatment of different donor microbiota.  
127x152mm (150 x 150 DPI)  
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